Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Next-Generation Sequencing Reveals a T Cell Receptor Signature Characteristic of Patients with Aplastic Anemia

Sofie Lundgren, BMed, Jani Huuhtanen, BMed, Mikko A Keränen, MD PhD, Cassandra M. Hirsch, Emmi Jokinen, MSc, Markus Heinonen, PhD, Paula Savola, MD, Tiina Kelkka, PhD, Freja Ebeling, MD PhD, Jaroslaw P. Maciejewski, Eva Hellström-Lindberg, MD PhD, Harri Lähdesmäki, PhD, Satu Mustjoki, MDPhD

Blood (2018) 132 (Supplement 1): 537.

https://doi.org/10.1182/blood-2018-99-117811

Published: 2018

Journal Articles

Polyclonal Immune Response in T-LGL Leads to Clonal Expansions Preceding Occurrence of STAT3 Mutations Further Solidifying Clonal Dominance

Cassandra M. Hirsch, Michael Clemente, MS, Peter Chomczynski, Bartlomiej P. Przychodzen, Yasunobu Nagata, Vera Adema, PhD, Louis Williams, MD MBA, Valeria Visconte, PhD, Alan Lichtin, MD, Satu Mustjoki, MDPhD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski

Blood (2018) 132 (Supplement 1): 516.

https://doi.org/10.1182/blood-2018-99-116307

Published: 2018

Journal Articles

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Muntasir M Majumder, MSc, BPharm, Maija Leppä, MSc(Tech), Monica Hellesoy, PhD, Paul Dowling, BSc, PhD, Alina Malyutina, Despina Bazou, BSc, MSc, PhD, Emma Irene Andersson, MSc, Alun Parsons, Jing Tang, PhD, Olli Kallioniemi, MD PhD, Satu Mustjoki, MDPhD, Peter O'Gorman, MD PhD FRCP, FRCPath, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Bjorn Gjertsen, MD PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 264.

https://doi.org/10.1182/blood-2018-99-118242

Published: 2018

Journal Articles

Somatic Mutations in CD8+ T Cells in Patients with Chronic Immune Thrombocytopenia Are Associated with Increased Clonality and Cytotoxic Phenotype of CD8+ T Cells

Hanna Rajala, MD PhD, Paula Savola, MD, Sofie Lundgren, BMed, Samuli Eldfors, PhD, Tiina Kelkka, PhD, Freja Ebeling, MD PhD, Satu Mustjoki, MDPhD

Blood (2018) 132 (Supplement 1): 131.

https://doi.org/10.1182/blood-2018-99-113373

Published: 2018

Journal Articles

Identification of Somatic Mutations in Expanded T Cell Clones of Patients with Chronic Graft-Versus-Host Disease (GVHD)

Giljun Park, PhD, Daehong Kim, Sofie Lundgren, Rajiv K Khajuria, Ana M Hurtado, Cecilia Muñoz-Calleja, Dra, Laura Cardeñoso, Samuli Eldfors, Pekka Ellonen, Sari Hannula, Oscar Brück, Anna Kreutzman, PhD, Andres Jerez, Maija Itälä-Remes, MD PhD, Mikko A Keränen, MD PhD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 4487.

https://doi.org/10.1182/blood.V130.Suppl_1.4487.4487

Published: 2017

Journal Articles

Low Expression of T/NK-Cell Signature Predicts Poor Survival in Patients with Primary Testicular and Diffuse Large B-Cell Lymphoma

Suvi-Katri Leivonen, PhD, Marjukka Pollari, MD, Oscar Brück, Teijo Pellinen, PhD, Marja-Liisa Karjalainen-Lindsberg, Susanna Mannisto, MD PhD, Pirkko-Liisa Kellokumpu-Lehtinen, MD prof, Satu Mustjoki, MDPhD, Sirpa Leppa, MD

Blood (2017) 130 (Supplement 1): 4027.

https://doi.org/10.1182/blood.V130.Suppl_1.4027.4027

Published: 2017

Journal Articles

High Amount of PD1+TIM3+ T Helper Cells May Predict Poor Outcome in Adult Acute Lymphoblastic Leukemia

Helena Hohtari, MD, Oscar Brück, Sami Blom, MSc, Riku Turkki, MSc, Antonio Ribeiro, BSc, Marjatta Sinisalo, MD PhD, Panu Kovanen, MD PhD, Olli Kallioniemi, MD PhD, Teijo Pellinen, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 3985.

https://doi.org/10.1182/blood.V130.Suppl_1.3985.3985

Published: 2017

Journal Articles

Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML

Heikki Kuusanmäki, MSc, Maija Leppä, BSc, Mika Kontro, MD, Olli Dufva, BSc, Debashish Deb, MSc, Bhagwan Yadav, PhD, Satu Mustjoki, MDPhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 3821.

https://doi.org/10.1182/blood.V130.Suppl_1.3821.3821

Published: 2017

Journal Articles

Acquired Somatic Mutations in T Cells in Patients with Aplastic Anemia and Hypoplastic Myelodysplastic Syndromes

Sofie Lundgren, Mikko Keränen, MD PhD, Kari Nousiainen, Samuli Eldfors, Sari Hannula, Tiina Hannunen, Pekka Ellonen, Gunilla Walldin, Michael Clemente, Freja Ebeling, MD PhD, Hanna Rajala, MD PhD, Jaroslaw P. Maciejewski, PhD MD FACP, Harri Lähdesmäki, PhD, Eva Hellstrom-Lindberg, MD PhD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 1169.

https://doi.org/10.1182/blood.V130.Suppl_1.1169.1169

Published: 2017

Journal Articles

Plasma Fms-Related Tyrosine Kinase 3 Ligand (Flt3L) Levels at Diagnosis Correlate with Treatment Response in Chronic Myeloid Leukemia

Bhagwan Yadav, PhD, Mette Ilander, PhD, Anna Kreutzman, PhD, Henrik Hjorth-Hansen, MD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 1602.

https://doi.org/10.1182/blood.V130.Suppl_1.1602.1602

Published: 2017

Journal Articles

Identification of Progression-Associated Mutations in Chronic Myeloid Leukemia (CML) By Comparative Genomic Analysis

Shady Adnan Awad, MD, Matti Kankainen, PhD, Samuli Eldfors, Bhagwan Yadav, PhD, Soili Kytölä, Pekka Ellonen, Mahmoud Kamel, MD PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 250.

https://doi.org/10.1182/blood.V130.Suppl_1.250.250

Published: 2017

Journal Articles

High Amount of PD-L1+ Tumor Associated Macrophages Is Associated with Better Survival in Patients with Primary Testicular Lymphoma

Marjukka Pollari, MD, Oscar Brück, Suvi-Katri Leivonen, PhD, Teijo Pellinen, PhD, Pauli Vähämurto, Marja-Liisa Karjalainen-Lindsberg, Susanna Mannisto, MD PhD, Pirkko-Liisa Kellokumpu-Lehtinen, MD prof, Satu Mustjoki, MDPhD, Sirpa Leppa, MD

Blood (2017) 130 (Supplement 1): 2761.

https://doi.org/10.1182/blood.V130.Suppl_1.2761.2761

Published: 2017

Journal Articles

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Susanne Saussele, MD, Johan Richter, MD PhD, Joelle Guilhot, PhD, Henrik Hjorth-Hansen, MD, Antonio Medina de Almeida, MD PhD, Jeroen J. W. M. Janssen, MD, Jiri Mayer, Prof, MD SCs, Perttu Koskenvesa, MD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Strömberg, MD PhD, Juan Luis Steegmann, MD PhD, Hanne Vestergaard, MD, Hans Ehrencrona, MD PhD, Veli Kairisto, Kateřina Machová Poláková, PhD, Martin Müller, MD, Satu Mustjoki, MDPhD, Marc G. Berger, MD PhD, Philippe Rousselot, Martine Escoffre-Barbe, MD, Gabriel Etienne, MD PhD, Jolanta Dengler, MD, Françoise Rigal-Huguet, MD, Nikolas von Bubnoff, MD, Hana Klamova, MD, Edgar Faber, MD, François Guilhot, MD, Kourosh Lotfi, MD, Delphine Rea, MD, Tim H. Brümmendorf, MD, Gorgine de Greef, MD, Leif Stenke, MD, Franck Emmanuel Nicolini, MD PhD, Laurence Legros, MD PhD, Andreas Burchert, MD, Jaroslava Voglová, MD, Aude Charbonnier, MD, Emmanuel Gyan, MDPhD, Maria-Elisabeth Goebeler, MD, Peter E. Westerweel, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 313.

https://doi.org/10.1182/blood.V130.Suppl_1.313.313

Published: 2017

Journal Articles

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Blood (2014) 124 (21): 812.

https://doi.org/10.1182/blood.V124.21.812.812

Published: 2014

Journal Articles

Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Leopold Sellner, MD, Malgorzata Oles, Tea Pemovska, MSc, Paavo Pietarinen, MSc, Anneli Lauhio, MD, Katarzyna Tomska, Carlos Cuesta-Mateos, MD PhD, Edgar Faber, Tim H. Brummendorf, MD PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD, Wolfgang Huber, PhD, Krister Wennerberg, PhD, Thorsten Zenz, MD, Satu Mustjoki, MDPhD

Blood (2014) 124 (21): 917.

https://doi.org/10.1182/blood.V124.21.917.917

Published: 2014

Journal Articles

Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies

Heikki Kuusanmäki, MSc, Hanna Rajala, MD PhD, Arjan van Adrichem, Muntasir Mamun Majumder, MSc,BPharm, Emma I Andersson, MSc, Krister Wennerberg, PhD, Satu Mustjoki, MDPhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 1771.

https://doi.org/10.1182/blood.V124.21.1771.1771

Published: 2014

Journal Articles

Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study

Blood (2014) 124 (21): 151.

https://doi.org/10.1182/blood.V124.21.151.151

Published: 2014

Journal Articles

A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses

Paavo Pietarinen, MSc, Tea Pemovska, MSc, Emma I Andersson, MSc, Perttu Koskenvesa, MD, Mika Kontro, MD, Swapnil Potdar, MSc, John Patrick Mpindi, MSc, Olli Kallioniemi, MD PhD, Krister Wennerberg, PhD, Caroline A Heckman, PhD, Satu Mustjoki, MDPhD, Kimmo Porkka, MD PhD

Blood (2014) 124 (21): 3139.

https://doi.org/10.1182/blood.V124.21.3139.3139

Published: 2014

Journal Articles

Dasatinib-Induced Reduction of Tumor Growth Is Accompanied By the Changes in the Immune Profile in a Melanoma B16.OVA Mouse Model

Mette Matilda Ilander, MSc, Can Hekim, PhD, Markus Vähä-Koskela, PhD, Paula Savola, Siri Tähtinen, MSc, Leena Saikko, Akseli Hemminki, MDPhD, Panu Kovanen, MDPhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MDPhD

Blood (2014) 124 (21): 1408.

https://doi.org/10.1182/blood.V124.21.1408.1408

Published: 2014

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Next-Generation Sequencing Reveals a T Cell Receptor Signature Characteristic of Patients with Aplastic Anemia

Polyclonal Immune Response in T-LGL Leads to Clonal Expansions Preceding Occurrence of STAT3 Mutations Further Solidifying Clonal Dominance

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Somatic Mutations in CD8+ T Cells in Patients with Chronic Immune Thrombocytopenia Are Associated with Increased Clonality and Cytotoxic Phenotype of CD8+ T Cells

Identification of Somatic Mutations in Expanded T Cell Clones of Patients with Chronic Graft-Versus-Host Disease (GVHD)

Low Expression of T/NK-Cell Signature Predicts Poor Survival in Patients with Primary Testicular and Diffuse Large B-Cell Lymphoma

High Amount of PD1+TIM3+ T Helper Cells May Predict Poor Outcome in Adult Acute Lymphoblastic Leukemia

Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML

Acquired Somatic Mutations in T Cells in Patients with Aplastic Anemia and Hypoplastic Myelodysplastic Syndromes

Plasma Fms-Related Tyrosine Kinase 3 Ligand (Flt3L) Levels at Diagnosis Correlate with Treatment Response in Chronic Myeloid Leukemia

Identification of Progression-Associated Mutations in Chronic Myeloid Leukemia (CML) By Comparative Genomic Analysis

High Amount of PD-L1+ Tumor Associated Macrophages Is Associated with Better Survival in Patients with Primary Testicular Lymphoma

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies

Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study

A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses

Dasatinib-Induced Reduction of Tumor Growth Is Accompanied By the Changes in the Immune Profile in a Melanoma B16.OVA Mouse Model

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only